Reviewing Enliven Therapeutics (NASDAQ:ELVN) and Fortress Biotech (NASDAQ:FBIOP)

Enliven Therapeutics (NASDAQ:ELVN) and Fortress Biotech (NASDAQ:FBIOP) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Earnings and Valuation

This table compares Enliven Therapeutics and Fortress Biotech’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$71.58 million	($1.93)	-12.26
Fortress Biotech	$82.62 million	N/A	N/A	N/A	N/A

Fortress Biotech has higher revenue and earnings than Enliven Therapeutics.

Insider & Institutional Ownership

95.1% of Enliven Therapeutics shares are held by institutional investors. 29.2% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Enliven Therapeutics and Fortress Biotech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	0	0	2	1	3.33
Fortress Biotech	0	0	0	0	N/A

Enliven Therapeutics presently has a consensus target price of $33.00, suggesting a potential upside of 39.42%. Given Enliven Therapeutics’ higher possible upside, equities research analysts clearly believe Enliven Therapeutics is more favorable than Fortress Biotech.

Profitability

This table compares Enliven Therapeutics and Fortress Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-28.83%	-27.05%
Fortress Biotech	N/A	N/A	N/A

Summary

Enliven Therapeutics beats Fortress Biotech on 5 of the 8 factors compared between the two stocks.

About Enliven Therapeutics

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

About Fortress Biotech

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.